Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $157.95 Consensus PT from Analysts
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy […]
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy […]
